At UCB, we embrace the possibility to transform the lives of people living with psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), systemic lupus erythematosus (SLE) and osteoporosis.
Despite the progress made in recent years, there remains a significant unmet need for people living with rheumatic diseases. We are hopeful, however, that the solid foundation established in partnership with the scientific community provides the opportunity to elevate care for people living with rheumatic diseases, allowing them to live as free as possible from the challenges and uncertainty caused by their disease.
Building on more than 30 years of research, we are now exploring approaches to move from symptomatic treatment to disease modification and cure. Our evolving rheumatology portfolio gives us the potential to deliver and expand value for numerous patient populations, including those living with axSpA, PsA and osteoporosis.
Through our unique mix of expertise, innovation and ambition, we aim to pioneer and accelerate scientific advancements which make a meaningful difference to people living with rheumatic diseases. Have a look at the infographic below to learn how UCB is aiming to transform rheumatology.
Inspired by patients, driven by science, we are UCB.